Brought to you by 
BMS, QDose end inhaled insulin product deal
17 Sep 2007
Executive Summary
QDose has licensed Bristol-Myers Squibb worldwide exclusive rights to its breath-activated, inhaled insulin product candidate. QDose is a JV owned by drug delivery company MicroDose Technologies and Quadrant Drug Delivery Ltd. (QDD; dry powder pulmonary delivery), the July 2003 management buyout of the former Elan Drug Delivery Ltd.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, QDose end inhaled insulin product deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice